The improvement of IIH with GLP-1 RAs is promising, but prospective, randomized controlled trials with larger cohorts are needed
However, driven by shifts in dietary patterns and rising obesity rates, its incidence and prevalence are steadily increasing, with the disease increasingly manifesting in younger individuals ( Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a novel class of antidiabetic agents that activate the GLP-1 receptor to stimulate insulin secretion and inhibit glucagon secretion in a glucose-dependent manner, delay gastric emptying, thereby controlling blood glucose and promoting weight loss ( Previous meta-analyses have primarily pooled the cardiovascular effects of GLP-1 RAs in patients with T2DM ( This study performed a systematic review and meta-analysis to evaluate the effects of subcutaneous vs
GLP-1 medicines have changed what is possible in obesity and type 2 diabetes, but they require chronic, high-dose systemic exposure that many patients cannot or do not sustain, said Harith Rajagopalan, MD, PhD, co-founder and CEO of Fractyl Health
Diarrhea from semaglutide is not a sign that the medication is failing or that you should stop treatment